CINF 21 |
| Therapeutic switching, the discovery and development of secondary uses for existing drugs, has three substantial advantages in terms of reduced risk, cost and time. Together with the opportunity created by new therapeutic use patents, this represents a highly efficient route to commercially protected new medicines. There are multiple classes of such programs, depending on whether the composition of matter patent supporting the original development is still in force, and whether the active ingredient was ever successfully developed for its original indication. However, the potential for off-label competition from generic products needs to be carefully considered in order to realise the optimal potential from this approach. Case histories will be presented, including examples in the fields of fibrosis and cachexia. These highlight (i) the value of new biology and (ii) the importance of differentiation among an ostensibly similar class of agents to identify improved non-genericisable therapeutics.
|
|
Drug Reprofiling
2:00 PM-5:40 PM, Sunday, August 19, 2007 BCEC -- 252 A, Oral
Division of Chemical Information |